The Cancer Tissue and Pathology Shared Resource facilitates discovery by providing high-quality biospecimens, expert pathology and laboratory services, advanced immune profiling technologies, and clinical research coordination to accelerate translational cancer research.
The Cancer Tissue and Pathology Shared Resource accelerates cancer research by providing integrated expertise, technologies, and infrastructure that enable investigators across all major and developing programs within Winship Cancer Institute of Emory University to acquire, analyze, and translate biospecimen-based data into impactful cancer research discoveries.
The Cancer Tissue and Pathology Shared Resource provides investigators across all major and developing programs within Winship Cancer Institute of Emory University with access to high-quality human biospecimens, clinical research coordination, histopathology, digital pathology, biobanking, immune monitoring, and advanced tissue analysis services. Through integrated patient consent, biospecimen procurement, clinical research support, laboratory processing, pathology expertise, and single-cell analytical technologies, the resource enables innovative translational cancer research and supports multidisciplinary team science across Winship Cancer Institute.
The Cancer Tissue and Pathology Shared Resource maintains a centralized biorepository that provides researchers with access to high-quality, clinically annotated biospecimens collected from consented patients across Winship Cancer Institute locations. The biorepository supports translational research through standardized collection, processing, storage, annotation, and distribution of biospecimens while maintaining strict regulatory compliance and quality assurance standards.
Available services include:
All specimens are managed using standardized operating procedures and tracked through secure laboratory information management systems to ensure specimen integrity, traceability, and efficient investigator access. The resource supports specimen collection and distribution across all major Winship disease groups and multiple clinical locations.
The Cancer Tissue and Pathology Shared Resource also provides centralized laboratory support for therapeutic clinical trials, including:
These services help ensure specimen integrity and support translational and correlative research objectives associated with therapeutic clinical trials.
The Cancer Tissue and Pathology Shared Resource administers the Winship Discovery Clinical Research Coordinator (CRC) team, which provides comprehensive support for non-therapeutic, observational, translational, and biospecimen-based research studies. The team works closely with investigators to facilitate study development, patient enrollment, specimen collection, and data acquisition.
Available CRC services include:
By integrating clinical research coordination with biorepository operations, the CRC team helps investigators efficiently conduct studies while ensuring high-quality data and biospecimen collection. The team supports a diverse portfolio of investigator-initiated research projects across multiple disease programs, including longitudinal treatment-response studies, biobanking initiatives, and community-based research efforts.
The Cancer Tissue and Pathology Shared Resource provides comprehensive histopathology and digital pathology services to support basic, translational, and clinical cancer research. Services are performed by experienced histology and pathology professionals using standardized, quality-controlled workflows to ensure reproducible, high-quality results. Investigators have access to routine and advanced tissue-based analytical services for both human and animal model specimens.
Available services include:
The Cancer Tissue and Pathology Shared Resource offers advanced immune monitoring services designed to support immuno-oncology, translational, and cellular therapy research. These services provide detailed characterization of immune responses and the tumor microenvironment through high-dimensional single-cell and functional immune assays.
Available technologies and services include:
The resource utilizes a Helios mass cytometer for high-parameter single-cell proteomic profiling and a CTL S6 Universal M2 ImmunoSpot analyzer for quantitative assessment of antigen-specific cellular immune responses. These capabilities complement histopathology and multiplex imaging services, enabling comprehensive characterization of cancer and immune cell populations.
The National Cancer Institute requires that publications acknowledge the Winship Cancer Institute Cancer Center Support Grant (CCSG), and it is tracking compliance. If a Winship Cancer Institute CCSG-supported Shared Resource provided data, designed the study, performed analyses, provided results used in your publication, and/or provided any systems or services that were used for the work that resulted in your publication, please include the following statement in the acknowledgment section of your publication(s):
Research reported in this publication was supported in part by the Cancer Tissue and Pathology Shared Resource of Winship Cancer Institute of Emory University and NIH/NCI under award number P30CA138292. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Winship Cancer Institute of Emory University
Winship Cancer Institute of Emory University
Winship Cancer Institute of Emory University
